论文部分内容阅读
针对以前的喹诺酮药的缺点,开发疗效超过现有喹诺酮药的新药继续成为研究热点。1995年7月在加拿大蒙特利尔召开的第19次国际化疗剂大会上报道了几个化合物的初步临床试验数据,包括辉瑞的超威沙星(trovafloxacin),大塚的格雷沙星(grepaflixacin),杏林的AM—1155,中外的巴罗沙星(balofloxacin)和日本新药的NM—441。这些药物中有两个新化合物,左氧沙星(第一制药的Cravit)和斯帕沙星(大日本的Spara)已在日本上市,后者也已在法国和卢森堡上市。特别是超威沙星,体内改善了对于肺炎链球菌的活性;格雷沙星改善了体外对于耐甲氧西林
In response to the shortcomings of previous quinolone drugs, the development of new drugs that outperform existing quinolone drugs continues to be a research hotspot. Preliminary clinical trial data for several compounds were reported at the 19th International Conference on Chemotherapy in July 1995 in Montreal, Canada, including trovafloxacin in Pfizer, grepaflixacin in Otsuka, AM-1155, balofloxacin both at home and abroad, and NM-441, a Japanese new drug. There are two new compounds in the drug, levofloxacin (Cravit from First Pharma) and sparfloxacin (Spara from Japan) are available in Japan, which is also listed in France and Luxembourg. Especially metsofloxacin, in vivo to improve the activity of Streptococcus pneumoniae; glirefloxacin improved in vitro against methicillin